-
Je něco špatně v tomto záznamu ?
Effects of morning vs. evening teriparatide injection on bone mineral density and bone turnover markers in postmenopausal osteoporosis
D. Michalska, M. Luchavova, V. Zikan, I. Raska, AA. Kubena, JJ. Stepan,
Jazyk angličtina Země Anglie, Velká Británie
Typ dokumentu časopisecké články, randomizované kontrolované studie, práce podpořená grantem
Grantová podpora
NS10564
MZ0
CEP - Centrální evidence projektů
Digitální knihovna NLK
Plný text - Článek
Zdroj
NLK
ProQuest Central
od 1997-01-01 do Před 1 rokem
Medline Complete (EBSCOhost)
od 2000-01-01 do Před 1 rokem
Nursing & Allied Health Database (ProQuest)
od 1997-01-01 do Před 1 rokem
Health & Medicine (ProQuest)
od 1997-01-01 do Před 1 rokem
Public Health Database (ProQuest)
od 1997-01-01 do Před 1 rokem
- MeSH
- bederní obratle patofyziologie MeSH
- biologické markery krev MeSH
- fosfáty krev MeSH
- inhibitory kostní resorpce aplikace a dávkování terapeutické užití MeSH
- injekce subkutánní MeSH
- izoenzymy krev MeSH
- kolagen typu I krev MeSH
- kostní denzita účinky léků MeSH
- kyselá fosfatasa krev MeSH
- lidé středního věku MeSH
- lidé MeSH
- peptidové fragmenty krev MeSH
- peptidy krev MeSH
- postmenopauzální osteoporóza krev farmakoterapie patofyziologie MeSH
- prokolagen krev MeSH
- rozvrh dávkování léků MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- teriparatid aplikace a dávkování terapeutické užití MeSH
- vápník krev MeSH
- Check Tag
- lidé středního věku MeSH
- lidé MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- randomizované kontrolované studie MeSH
UNLABELLED: A 12-month morning teriparatide (TPTD) administration resulted in a larger increase in the lumbar spine bone mineral density (BMD) than the evening application. The results indicate that the response of bone cells to teriparatide treatment depends on dosing time. INTRODUCTION: The aim of this study was to assess the long-term effects of the morning vs. the evening teriparatide administration on BMD and bone turnover markers (BTMs) in postmenopausal osteoporosis. METHODS: Fifty women with established postmenopausal osteoporosis were randomized to 12-month treatment with 20 μg of TPTD, administered daily in the morning or in the evening. The BMD and serum concentrations of C-terminal telopeptide of type I collagen, N-terminal propeptide of type I procollagen (PINP), and tartrate-resistant acid phosphatase isoform 5b (TRAP 5b) were measured at baseline, after 6 and 12 months. General linear model-repeated measurements were used to analyze the data. RESULTS: After 12 months, the lumbar spine BMD grew markedly (p < 0.001) with a significantly greater increase in the morning arm compared to the evening arm (9.1% vs. 4.8%, respectively, p < 0.05). The BMD at the distal radius significantly decreased (p < 0.001), with no differences between the arms. The BMD at proximal femur did not change significantly. After 6 months, the BTMs were significantly increased compared with baseline (p < 0.001). The increases in the evening arm vs. the morning arm, however, were more pronounced in PINP (+358% vs. +215%, respectively) and in TRAP 5b (+70% vs. +37%, respectively) (both p < 0.05). CONCLUSION: 12-month morning administration of TPTD resulted in a larger increase in the lumbar spine BMD than the evening application. The timing of TPTD administration may be important for its efficacy.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc13024459
- 003
- CZ-PrNML
- 005
- 20141023103750.0
- 007
- ta
- 008
- 130703s2012 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1007/s00198-012-1955-4 $2 doi
- 035 __
- $a (PubMed)22426952
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Michalska, D $u Department of Internal Medicine III-Department of Endocrinology and Metabolism, General University Hospital and First Faculty of Medicine, Charles University, Prague, U Nemocnice 1, 128 08, Prague 2, Czech Republic.
- 245 10
- $a Effects of morning vs. evening teriparatide injection on bone mineral density and bone turnover markers in postmenopausal osteoporosis / $c D. Michalska, M. Luchavova, V. Zikan, I. Raska, AA. Kubena, JJ. Stepan,
- 520 9_
- $a UNLABELLED: A 12-month morning teriparatide (TPTD) administration resulted in a larger increase in the lumbar spine bone mineral density (BMD) than the evening application. The results indicate that the response of bone cells to teriparatide treatment depends on dosing time. INTRODUCTION: The aim of this study was to assess the long-term effects of the morning vs. the evening teriparatide administration on BMD and bone turnover markers (BTMs) in postmenopausal osteoporosis. METHODS: Fifty women with established postmenopausal osteoporosis were randomized to 12-month treatment with 20 μg of TPTD, administered daily in the morning or in the evening. The BMD and serum concentrations of C-terminal telopeptide of type I collagen, N-terminal propeptide of type I procollagen (PINP), and tartrate-resistant acid phosphatase isoform 5b (TRAP 5b) were measured at baseline, after 6 and 12 months. General linear model-repeated measurements were used to analyze the data. RESULTS: After 12 months, the lumbar spine BMD grew markedly (p < 0.001) with a significantly greater increase in the morning arm compared to the evening arm (9.1% vs. 4.8%, respectively, p < 0.05). The BMD at the distal radius significantly decreased (p < 0.001), with no differences between the arms. The BMD at proximal femur did not change significantly. After 6 months, the BTMs were significantly increased compared with baseline (p < 0.001). The increases in the evening arm vs. the morning arm, however, were more pronounced in PINP (+358% vs. +215%, respectively) and in TRAP 5b (+70% vs. +37%, respectively) (both p < 0.05). CONCLUSION: 12-month morning administration of TPTD resulted in a larger increase in the lumbar spine BMD than the evening application. The timing of TPTD administration may be important for its efficacy.
- 650 _2
- $a kyselá fosfatasa $x krev $7 D000135
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a senioři nad 80 let $7 D000369
- 650 _2
- $a biologické markery $x krev $7 D015415
- 650 _2
- $a kostní denzita $x účinky léků $7 D015519
- 650 _2
- $a inhibitory kostní resorpce $x aplikace a dávkování $x terapeutické užití $7 D050071
- 650 _2
- $a vápník $x krev $7 D002118
- 650 _2
- $a kolagen typu I $x krev $7 D024042
- 650 _2
- $a rozvrh dávkování léků $7 D004334
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a injekce subkutánní $7 D007279
- 650 _2
- $a izoenzymy $x krev $7 D007527
- 650 _2
- $a bederní obratle $x patofyziologie $7 D008159
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a postmenopauzální osteoporóza $x krev $x farmakoterapie $x patofyziologie $7 D015663
- 650 _2
- $a peptidové fragmenty $x krev $7 D010446
- 650 _2
- $a peptidy $x krev $7 D010455
- 650 _2
- $a fosfáty $x krev $7 D010710
- 650 _2
- $a prokolagen $x krev $7 D011347
- 650 _2
- $a teriparatid $x aplikace a dávkování $x terapeutické užití $7 D019379
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a randomizované kontrolované studie $7 D016449
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Luchavova, M $u -
- 700 1_
- $a Zikan, V $u -
- 700 1_
- $a Raska, I $u -
- 700 1_
- $a Kubena, A A $u -
- 700 1_
- $a Stepan, J J $u -
- 773 0_
- $w MED00003659 $t Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA $x 1433-2965 $g Roč. 23, č. 12 (2012), s. 2885-91
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/22426952 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20130703 $b ABA008
- 991 __
- $a 20141023103748 $b ABA008
- 999 __
- $a ok $b bmc $g 988139 $s 822839
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2012 $b 23 $c 12 $d 2885-91 $i 1433-2965 $m Osteoporosis international $n Osteoporos Int $x MED00003659
- GRA __
- $a NS10564 $p MZ0
- LZP __
- $a Pubmed-20130703